← Regeneron Pharmaceuticals overview

Regeneron Pharmaceuticals vs Novartis: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Regeneron Pharmaceuticals Inc (REGN)

Q3 2026
▲2▼2

Regeneron's Q3: pipeline wins, Sanofi deal, but melanoma setback

  • Strong Q2 results and pipeline progress Regeneron reported Q2 revenue up 17% to $4.29 billion, received FDA priority review for cemdisiran in myasthenia gravis, and won approval for Pasatru in FOP disease. These advances support future growth.

    These positive developments drove investor optimism and supported the stock.

  • Expanded Sanofi deal and obesity drug data Regeneron expanded its Sanofi partnership with $1 billion upfront and four pipeline therapies. Its obesity drug trevogrumab preserved about 70% of muscle loss in a Phase 2 trial, showing promise in a large market.

    The deal and trial data are new positive catalysts for Regeneron's growth outlook.

  • Failed melanoma trial and lawsuits A failed melanoma trial led to class-action lawsuits and an $11 billion market-value loss. This setback raised concerns about pipeline execution and weighed on the stock.

    This was a major negative event that hurt investor confidence and the share price.

  • Eylea competition and Sanofi deal disappointment Eylea faces biosimilar and competitive threats, notably Kodiak's less-frequent-dosing eye drug. The Sanofi deal left Dupixent profit-sharing unchanged, disappointing some investors and briefly pressuring shares.

    These competitive and deal-related concerns created headwinds for the stock.

August 2026
▲2▼1

Regeneron's strong Q2 and pipeline wins offset by legal and competitive risks

  • Strong Q2 earnings and margin improvement Regeneron beat Q2 estimates with revenue up 17% to $4.29 billion, driven by Dupixent and high-dose Eylea. Repaying the Sanofi Development Balance should improve margins, and buybacks and dividends support shareholder value.

    This point explains the positive financial performance that drove the stock during the period.

  • Pipeline progress and new Sanofi deal FDA approval of Pasatru for rare FOP disease validates Regeneron's drug platform. A new Sanofi deal adds $1 billion upfront and four pipeline therapies, strengthening the pipeline and providing external validation.

    This point highlights key pipeline and partnership developments that boosted investor sentiment.

  • Pipeline uncertainty and Eylea competition Mixed melanoma trial results and increasing competition for Eylea add pipeline uncertainty. These factors offset strong commercial performance and contribute to a balanced but cautious outlook.

    This point explains the competitive and pipeline challenges that acted as a counterweight to positive developments.

Latest
▲2▼2

Regeneron's Sanofi deal and pipeline progress offset by Eylea competition and lawsuits

  • Sanofi deal expands pipeline with $1B upfront Regeneron and Sanofi agreed to jointly develop four long-acting immunology therapies, led by REGN20423, in a deal worth up to $8 billion including $1 billion upfront. This brings cash and pipeline growth, supporting future revenue and the stock.

    This is a major new partnership that directly boosts Regeneron's pipeline and cash, a key positive driver.

  • Securities class action lawsuits weigh on sentiment Multiple law firms filed class actions alleging Regeneron made false statements about its Fianlimab-Libtayo trial, causing investor losses. The legal uncertainty and potential reputational damage pressure the stock, though the company denies wrongdoing.

    These lawsuits are a new negative overhang that could affect investor confidence and lead to financial penalties.

  • Mixed melanoma trial results lead to pullback Regeneron's melanoma drug trial produced mixed results, causing shares to give back some gains. This setback raises doubts about the drug's potential and adds to pipeline uncertainty, weighing on the stock.

    This is a new clinical setback that directly impacts Regeneron's oncology pipeline and investor expectations.

  • Buybacks and dividend support shareholder value Regeneron confirmed its quarterly dividend, updated on share repurchases, and reported Q2 results. With the stock trading below fair value estimates, these capital returns and pipeline progress support the shares.

    This shows management's commitment to returning cash and the stock's valuation appeal, a positive for investors.

September 2026
▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

  • Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

    This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

  • Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

    A positive clinical readout in a major new market area is a key driver of future growth expectations.

  • Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

    Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

  • Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

    It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

  • Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

    This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

  • Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

    A positive clinical readout in a major new market area is a key driver of future growth expectations.

  • Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

    Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

  • Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

    It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

  • Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.

    This is the period's biggest positive fundamental driver of REGN's value.

  • Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.

    It is a concrete capital event that improves future profitability.

  • FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.

    A new FDA approval is a fresh product and pipeline milestone for REGN.

  • Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.

    This is the main negative overhang on REGN this period.

July 2026
▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

  • Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

    This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

  • Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

    This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

  • Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

    This new analyst commentary underscores pipeline challenges that could pressure the stock.

▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

  • Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

    This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

  • Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

    This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

  • Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

    This new analyst commentary underscores pipeline challenges that could pressure the stock.

Q2 2026
▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

June 2026
▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

Novartis AG (NOVN.SW)

Q3 2026
▼4▲3

Novartis Q3: Approvals and Deals Offset Entresto Plunge and Trial Failures

  • EU approval of Itvisma gene therapy Novartis won European approval for Itvisma, a one-time gene therapy for a rare genetic disorder. This adds a new high-value treatment to its portfolio and supports future revenue growth.

    New approval is a concrete positive catalyst for the stock.

  • FDA full approval of Fabhalta The FDA granted full approval to Fabhalta for a rare kidney disease, removing a prior restriction. This expands the patient population and strengthens Novartis's rare-disease franchise.

    Full approval is a new milestone that can boost sales and sentiment.

  • Q2 earnings beat and return to sales growth Novartis reported second-quarter results that beat expectations, with sales returning to growth. This reassured investors that the core business remains healthy despite patent challenges.

    Earnings beat is a key driver of stock performance in the quarter.

  • Entresto sales plunge 50% on generics Sales of heart drug Entresto fell by half as generic competitors entered the market, costing about $4 billion in annual revenue. This is a major headwind to earnings and growth.

    The loss of a top-selling drug's exclusivity is a significant negative force.

  • Late-stage trial failures for pelacarsen and del-desiran Two experimental drugs, pelacarsen for heart disease and del-desiran for a muscle disorder, failed in late-stage trials. These setbacks reduce the pipeline's potential and raise doubts about future growth.

    Trial failures are a direct negative for pipeline value and investor confidence.

  • Eight CAR-T trials paused after patient deaths Novartis paused eight CAR-T cancer trials following patient deaths. This raises safety concerns, delays potential new treatments, and could hurt its oncology reputation.

    Safety issues can derail a promising area and weigh on the stock.

  • Activist investor demands board overhaul amid high debt Top shareholder Artisan Partners pushed for a board shake-up, citing $39.4 billion in net debt. This adds governance uncertainty and pressure on management to improve performance.

    Activist pressure can lead to strategic changes and short-term volatility.

  • Pipeline wins and acquisitions offset setbacks Novartis advanced remibrutinib, expanded Pluvicto's label, and acquired Myricx Bio and Tourmaline Bio in deals worth billions. These moves show continued investment in innovation despite recent failures.

    These positive pipeline and deal activities are new and balance the negative news.

August 2026
▲3▼1

Pipeline wins and deals offset CAR-T safety setback

  • Remibrutinib MS and hives approvals Remibrutinib won two Phase 3 MS trials and gained FDA approval (Rhapsido) for chronic hives, adding a new revenue stream and strengthening the company's immunology franchise.

    This is a major pipeline win that supports future growth and was not in earlier reports.

  • Pluvicto expanded to earlier prostate cancer Pluvicto was approved for earlier prostate cancer, nearly doubling the number of eligible patients. This expands the market for an existing drug and could significantly boost sales.

    This approval opens a larger patient population and is a new positive catalyst for the stock.

  • Tourmaline Bio acquisition and licensing deals Novartis acquired Tourmaline Bio for $1.4 billion, adding a Phase III cardiovascular drug, and signed licensing deals with Alteogen (up to $3.2 billion) and Abogen (up to $7.8 billion).

    These deals bolster the pipeline and show strategic investment in future growth, a new development this period.

  • CAR-T trial pause and pelacarsen failure Eight CAR-T trials were paused after three patient deaths, raising safety and regulatory risk. Pelacarsen failed its main Phase 3 heart trial goal, removing a growth driver. Shares already trade above many value estimates.

    These setbacks are new negative developments that could pressure the stock and offset positive news.

Latest
▲4

Novartis wins new drug approvals and deals, but pipeline setbacks linger

  • FDA approves Pluvicto for earlier prostate cancer The FDA approved Pluvicto for metastatic hormone-sensitive prostate cancer, nearly doubling the eligible patient population. This expands sales of an already marketed drug and strengthens Novartis's position in radioligand therapy, supporting future revenue growth.

    This is a new regulatory approval that directly expands the market for a key Novartis product.

  • FDA approves Rhapsido for chronic hives The FDA approved Rhapsido (remibrutinib) as the first treatment for symptomatic dermographism, a form of chronic hives. This adds a new approved indication for an oral drug that is also being tested in multiple sclerosis, broadening its potential sales.

    A new FDA approval that opens an additional market for a pipeline drug.

  • Novartis buys Tourmaline Bio for $1.4 billion Novartis agreed to acquire Tourmaline Bio for about $1.4 billion, adding pacibekitug, a Phase III-ready anti-inflammatory drug for heart and kidney diseases. This strengthens its cardiovascular pipeline and shows it is still investing in new science despite recent trial failures.

    A major acquisition that adds a late-stage asset and signals continued pipeline investment.

  • New licensing deal with Abogen worth up to $7.8 billion Novartis signed a licensing and option agreement with China's Abogen Biosciences for its lead mRNA cancer asset, ABO2203, worth up to $7.8 billion including $575 million upfront. This adds a new cancer candidate and shows Novartis can attract outside innovation.

    A large new deal that brings in a new pipeline asset and demonstrates deal-making ability.

September 2026
▼2▲1

Pipeline failures and governance pressure hit Novartis in September

  • Late-stage trial failures Pelacarsen and del-desiran failed late-stage trials, erasing billions in potential revenue and market value, while ALS drug rifonebart was halted. These setbacks hurt sentiment and raised doubts about the pipeline.

    Major negative news that directly impacted investor confidence and valuation.

  • Governance pressure from top shareholder Top shareholder Artisan Partners demanded a board overhaul over dealmaking, with net debt at $39.4 billion and eight shareholders raising concerns. This adds uncertainty about strategy and capital allocation.

    Governance issues can weigh on stock price and investor trust.

  • Pipeline wins and licensing deals Remibrutinib showed best-in-class potential in MS, Cosentyx won EU backing for polymyalgia rheumatica, and Novartis signed licensing deals worth up to $8.1 billion plus acquired Sironax's brain-delivery platform, signaling continued investment in innovation.

    Positive pipeline news and deals support future growth despite recent failures.

▲2▼2

Novartis adds two big pipeline deals; board pressure and CAR-T pause persist

  • Novartis licenses two new pipeline assets in deals worth up to $8.1 billion Novartis signed a radioligand therapy license with BoomRay (up to $900 million) and an mRNA T-cell engager deal with Abogen (up to $7.2 billion). These add new cancer and autoimmune candidates, showing Novartis can still attract outside innovation and giving investors fresh growth hopes after recent trial failures.

    These are the period's only new positive events and directly counter the pipeline-failure narrative that has weighed on the stock.

  • Artisan Partners publicly demands board shake-up over deal oversight Top-20 shareholder Artisan Partners called for a board overhaul after trial failures wiped out $30 billion in market value. Eight shareholders have raised concerns about Novartis' acquisition strategy. This governance pressure keeps uncertainty high and can weigh on the shares until management responds.

    It is a new escalation of shareholder activism that directly questions Novartis' dealmaking and board, a key overhang on the stock.

  • CAR-T trial pause after three patient deaths continues to raise safety concerns Novartis paused eight rap-cel CAR-T trials in autoimmune and neurological diseases after three deaths from a severe immune reaction. The disclosure came only after an analyst noticed the halted trials. This adds regulatory and safety risk, delaying a promising new treatment area and weighing on sentiment.

    It is a new negative safety event that adds to Novartis' pipeline setbacks and can pressure the share price until reviews clear.

  • EU panel backs Cosentyx for polymyalgia rheumatica, expanding a key drug A European Medicines Agency committee recommended approving Cosentyx for polymyalgia rheumatica, a painful inflammatory condition. If the European Commission agrees, it would be the first IL-17A inhibitor cleared for this disease in Europe, adding sales for an already marketed drug and offering a modest lift.

    It is a new regulatory win that expands an existing blockbuster into a new indication, supporting near-term revenue growth.

▲2▼2

Novartis hit by three trial failures; pipeline doubts deepen

  • ALS drug rifonebart halted after mid-stage failure Novartis stopped developing its ALS drug rifonebart after it failed its main and secondary goals in a mid-stage trial of 251 patients. This adds to a string of pipeline setbacks, making investors doubt Novartis's ability to turn research spending into new products and pressuring the shares.

    New pipeline failure that directly adds to negative sentiment and future growth doubts.

  • Novartis buys Sironax brain-delivery platform for $125 million Novartis exercised an option to acquire Sironax's brain-delivery technology for $125 million, gaining a way to get large drugs across the blood-brain barrier. This modestly strengthens its neurology pipeline and shows it is still investing in new science despite recent failures.

    New deal that shows continued pipeline investment and a small positive counterweight.

  • EU panel backs Cosentyx for polymyalgia rheumatica A European Medicines Agency committee recommended approving Cosentyx for polymyalgia rheumatica, a painful inflammatory condition. If the European Commission agrees, it would be the first IL-17A inhibitor cleared for this disease in Europe, expanding sales for an already marketed drug and offering a small lift.

    New regulatory win that broadens an existing product's label and provides a positive offset.

  • Board pressure and $39.4 billion net debt raise capital concerns After the del-desiran failure, top shareholder Artisan Partners demanded a board overhaul, and reports highlighted that Novartis spent over $30 billion on deals, pushing net debt to $39.4 billion. This raises doubts about dealmaking discipline and leaves less room for error, weighing on the stock.

    New details on activist pressure and balance-sheet strain that affect investor confidence.

▼3▲1

Novartis hit by two trial failures, board pressure; MS drug offers hope

  • Pelacarsen heart drug fails, wiping out $6B opportunity Novartis's cholesterol drug pelacarsen failed a final-stage trial, losing a potential $3–6 billion-a-year seller. The news sent shares down 3.3% and removed a key growth driver, making investors question the company's pipeline.

    This is a major pipeline failure that directly hurt the stock and shifts focus to remaining drugs.

  • Muscle-wasting drug del-desiran fails, shares plunge 10–13% The lead asset from Novartis's $12 billion Avidity acquisition failed its pivotal trial, erasing about CHF24–30 billion in market value. This is the third setback in a week and raises doubts about the company's deal-making and pipeline.

    This is the biggest new negative event, causing a record share drop and directly impacting valuation.

  • Top shareholder Artisan Partners demands board shake-up After the record share fall, Artisan Partners publicly urged Novartis to overhaul its board and deal team, citing failed acquisitions. This adds governance and reputational pressure, which can weigh on the stock until management responds.

    This is a new activist investor move that increases uncertainty and could force changes, affecting investor confidence.

  • Remibrutinib beats Sanofi's Aubagio in two late-stage MS trials Novartis's oral MS drug remibrutinib outperformed an older treatment, showing best-in-class potential with no liver-safety issues. Analysts see up to $9 billion in peak sales, offering a bright spot amid recent failures and supporting future growth.

    This is the main positive counterweight, showing pipeline strength and potential to offset losses.

▲2▼2

Novartis pipeline swings: MS win, CAR-T pause, heart drug miss

  • CAR-T trial halt after three deaths Novartis paused eight CAR-T trials for autoimmune and neurological diseases after three patients died from a severe immune reaction. This raises safety and regulatory risk, delays a promising new treatment area, and can weigh on the share price until reviews clear.

    A major safety setback that directly threatens a key pipeline and investor confidence.

  • Remibrutinib wins two Phase 3 MS trials The oral drug remibrutinib beat teriflunomide on relapses and brain lesions in two late-stage MS trials, with no liver-safety worry. This opens a large new market and drove the stock up about 6%, though the shares already trade above many value estimates.

    The period's biggest positive catalyst, with clear efficacy and a large commercial opportunity.

  • Pelacarsen fails main heart trial goal Partner Ionis said Novartis' pelacarsen lowered Lp(a) levels but did not reduce major heart events versus placebo in a Phase 3 trial. This removes a potential growth driver for a common inherited heart risk, hurting sentiment on Novartis' cardiovascular pipeline.

    A late-stage failure that erases a hoped-for new revenue source and dents pipeline credibility.

  • Alteogen deal for subcutaneous versions Novartis signed an option and license deal with Alteogen to turn some intravenous biologics into easier subcutaneous shots, with up to $3.2 billion in potential payments. This could extend the life and convenience of existing products, a modest positive for the pipeline.

    A new partnership that supports future product lifecycles and is not already covered.

July 2026
▲4▼2

Novartis pipeline wins and earnings beat offset Entresto decline

  • EU approval for Itvisma gene therapy Novartis received EU approval for its Itvisma gene therapy, adding a new treatment option and reinforcing its position in advanced therapies. This expands the company's portfolio and offers a potential new revenue stream.

    This is a new regulatory win that supports future growth.

  • FDA full approval for Fabhalta in kidney disease The FDA granted full approval for Fabhalta in kidney disease, transitioning from accelerated approval. This validates the drug's efficacy and allows broader marketing, potentially boosting sales in a new indication.

    This is a new regulatory milestone that could drive revenue.

  • $1.5B Myricx Bio acquisition Novartis acquired Myricx Bio for $1.5 billion, adding a new asset to its pipeline. This strategic move aims to bolster future growth through external innovation.

    This is a new acquisition that expands the pipeline.

  • Q2 earnings beat with sales returning to growth Novartis reported Q2 earnings that beat expectations, with sales returning to growth despite Entresto's decline. This shows resilience and operational execution, reassuring investors about the company's trajectory.

    This is a new financial result that positively surprised the market.

  • Entresto sales plunge 50% on generics Entresto sales fell 50% as generic competition entered the market, resulting in a $4 billion annual revenue hit. This significant loss pressures overall growth and profitability.

    This is a new negative development impacting financials.

  • UBS turns cautious on Novartis relative to peers UBS downgraded its view on Novartis, citing relative underperformance compared to AstraZeneca and Roche. This cautious stance may limit upside and affect investor sentiment.

    This is a new analyst action that could weigh on the stock.

  • High-stakes late-stage trials could add $10B+ but face failure risk Three late-stage trials (pelacarsen, remibrutinib, del-desiran) could add over $10 billion in sales, but Goldman Sachs warns the stock could suffer if at least two fail. This creates meaningful pipeline uncertainty.

    This is a new analyst warning about pipeline risk.

▲2▼1

Novartis wins FDA label expansions, Q2 beat, but Entresto cliff and pipeline risk loom

  • FDA full approval for Fabhalta in kidney disease The FDA granted full approval to Fabhalta for slowing kidney decline in IgA nephropathy, upgrading it from accelerated approval. This expands the market for a first-in-class oral drug and adds a new growth driver, supporting the stock.

    This is a new regulatory win that directly boosts Novartis's revenue outlook.

  • Q2 earnings beat and sales return to growth Novartis beat second-quarter profit and sales estimates, with key brands like Kisqali and Pluvicto growing strongly. Sales returned to growth despite Entresto's 50% decline, reassuring investors and lifting the stock.

    The earnings beat is a new event that shows the company's core business is performing better than expected.

  • Entresto sales plunge 50% on generics Entresto sales fell 50% to $1.18 billion as cheaper generics entered the market, a $4 billion annual revenue hit. This drags on overall growth and pressures the stock, though newer drugs are offsetting some of the loss.

    This is a major negative force that explains why Novartis's growth is muted and why the stock faces a headwind.

  • Pipeline bets face high-stakes trial readouts Novartis is relying on three late-stage trials (pelacarsen, remibrutinib, del-desiran) that could add over $10 billion in sales, but Goldman Sachs warns the stock could suffer if at least two fail. This creates uncertainty around future growth.

    This highlights the key risk and potential reward that will drive the stock's longer-term direction.

▲3▼1

Novartis advances gene therapy and oncology pipeline, but UBS turns cautious

  • EU approval for Itvisma gene therapy Novartis won European Commission approval for Itvisma, a one-time gene replacement therapy for spinal muscular atrophy in patients aged 2 and older. This expands its approved product portfolio in Europe and opens a new revenue stream, supporting the stock.

    This is a concrete regulatory win that directly adds a new approved product and potential sales.

  • Acquisition of Myricx Bio for up to $1.5B Novartis agreed to buy UK biotech Myricx Bio for up to $1.5 billion, gaining a first-in-class antibody-drug conjugate payload platform and two lead assets. This strengthens its oncology pipeline and shows commitment to high-growth areas, a positive for the stock.

    This is a major strategic deal that bolsters the pipeline and signals growth investment.

  • ianalumab positioned in growing markets Novartis' ianalumab is highlighted as a key late-stage candidate in warm autoimmune hemolytic anemia and systemic lupus erythematosus, both large markets with no approved therapies. Phase III results are expected in 2027, offering a potential future growth driver.

    This points to a significant pipeline opportunity that could drive future revenue.

  • UBS cautious on Novartis UBS reiterated an overweight view on European pharma but was more cautious on Novartis, preferring peers like AstraZeneca and Roche. This relative caution may weigh on sentiment and limit the stock's upside compared to sector peers.

    This is a direct analyst opinion that could influence investor perception and relative performance.

Q2 2026
▲3▼1

Novartis pipeline wins offset patent loss in radioligand therapy

  • Patent loss opens door to competitor in key cancer therapy A US court invalidated Novartis patents on its Lutathera radioligand therapy, allowing Curium to launch a competing version. This threatens future sales of a key product, weighing on the stock.

    This is a new negative regulatory event that directly challenges Novartis's radioligand franchise.

  • Positive Phase III data for Rhapsido in chronic inducible urticaria Novartis reported that Rhapsido met primary endpoints in a Phase III trial for chronic inducible urticaria, becoming the first to show efficacy in this condition. This supports a potential new growth driver.

    New clinical success expands the pipeline and boosts confidence in future revenue.

  • Early promise for del-brax in rare muscle disease Novartis's experimental drug del-brax showed promise in an early trial for FSHD, lowering disease markers and muscle damage. If approved, it could be the first disease-modifying treatment, adding a new rare-disease asset.

    New positive trial data for a potential first-in-class therapy supports long-term growth.

  • Oncology deals and market growth outlook Novartis announced two oncology partnerships (Antares, Orionis) worth up to $3.3 billion and a market report projected its radioligand therapy sales to reach $30 billion by 2034. These reinforce its pipeline and leadership in a high-growth area.

    New deals and market forecast highlight Novartis's strategy to offset patent losses and drive future sales.

June 2026
▲3▼1

Novartis pipeline wins offset patent loss in radioligand therapy

  • Patent loss opens door to competitor in key cancer therapy A US court invalidated Novartis patents on its Lutathera radioligand therapy, allowing Curium to launch a competing version. This threatens future sales of a key product, weighing on the stock.

    This is a new negative regulatory event that directly challenges Novartis's radioligand franchise.

  • Positive Phase III data for Rhapsido in chronic inducible urticaria Novartis reported that Rhapsido met primary endpoints in a Phase III trial for chronic inducible urticaria, becoming the first to show efficacy in this condition. This supports a potential new growth driver.

    New clinical success expands the pipeline and boosts confidence in future revenue.

  • Early promise for del-brax in rare muscle disease Novartis's experimental drug del-brax showed promise in an early trial for FSHD, lowering disease markers and muscle damage. If approved, it could be the first disease-modifying treatment, adding a new rare-disease asset.

    New positive trial data for a potential first-in-class therapy supports long-term growth.

  • Oncology deals and market growth outlook Novartis announced two oncology partnerships (Antares, Orionis) worth up to $3.3 billion and a market report projected its radioligand therapy sales to reach $30 billion by 2034. These reinforce its pipeline and leadership in a high-growth area.

    New deals and market forecast highlight Novartis's strategy to offset patent losses and drive future sales.

▲3▼1

Novartis pipeline wins offset patent loss in radioligand therapy

  • Patent loss opens door to competitor in key cancer therapy A US court invalidated Novartis patents on its Lutathera radioligand therapy, allowing Curium to launch a competing version. This threatens future sales of a key product, weighing on the stock.

    This is a new negative regulatory event that directly challenges Novartis's radioligand franchise.

  • Positive Phase III data for Rhapsido in chronic inducible urticaria Novartis reported that Rhapsido met primary endpoints in a Phase III trial for chronic inducible urticaria, becoming the first to show efficacy in this condition. This supports a potential new growth driver.

    New clinical success expands the pipeline and boosts confidence in future revenue.

  • Early promise for del-brax in rare muscle disease Novartis's experimental drug del-brax showed promise in an early trial for FSHD, lowering disease markers and muscle damage. If approved, it could be the first disease-modifying treatment, adding a new rare-disease asset.

    New positive trial data for a potential first-in-class therapy supports long-term growth.

  • Oncology deals and market growth outlook Novartis announced two oncology partnerships (Antares, Orionis) worth up to $3.3 billion and a market report projected its radioligand therapy sales to reach $30 billion by 2034. These reinforce its pipeline and leadership in a high-growth area.

    New deals and market forecast highlight Novartis's strategy to offset patent losses and drive future sales.